iBio is an innovator biologics company developing therapeutics and vaccines for the betterment of human and animal health with pipeline candidates targeting systemic sceleroderma (IBIO-100), COVID-19 (IBIO-200 and IBIO-201), and classical swine fever (IBIO-400). iBio’s subsidiary, iBio CDMO is a global leader in plant-based manufacturing. It’s FastPharming® and FastGlycaneering™ platforms provide contract development and manufacturing services via its 130,000 square foot facility in Bryan, Texas. The speed and scalability of FastPharming make it an ideal choice for other innovator companies who want to rapidly produce biologics.
Ticker:
IBIO
Exchange:
NYSE
Company Type:
Publicly Traded Company
Company Website:
Company HQ State:
Texas
Company HQ Country:
United States
Year Founded:
Not Provided
Main Therapeutic Focus:
Respiratory
Lead Product in Development:
IBIO-100
Development Phase of Primary Product:
Pre-Clinical
Number Of Unlicensed Products (For Which You Are Seeking Partners):
4
Speaker
BIO DOUBLE HELIX SPONSORS
BIO HELIX SPONSORS
